Targeting a protein pathway to improve cancer immunotherapy
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
This study is looking at a protein called GRP94 to see how it affects cancer and the immune system, with the hope of finding new ways to improve cancer treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10906122 on NIH RePORTER |
What this research studies
This research investigates the role of GRP94, a protein that helps control various cellular processes, in cancer treatment. By focusing on how GRP94 interacts with other molecules involved in immune response and cancer growth, the research aims to develop new immunotherapy strategies. The approach includes studying the mechanisms by which GRP94 influences cancer cell behavior and immune evasion, particularly through a molecule called GARP. The ultimate goal is to identify new therapeutic targets that could enhance the effectiveness of cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who may benefit from enhanced immunotherapy options.
Not a fit: Patients with non-cancerous conditions or those who do not respond to immunotherapy may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that improve patient outcomes.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for cancer treatment, indicating potential for success in this approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Li, Zihai — Ohio State University
- Study coordinator: Li, Zihai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.